Is DIARRHOEA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DIARRHOEA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 613 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DIARRHOEA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DIARRHOEA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DIARRHOEA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DIARRHOEA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DIARRHOEA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DIARRHOEA: 613
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DIARRHOEA is a reported side effect: 18.4139%

FDA reports of any drug causing DIARRHOEA : 123783
Average percentage for all medicated patients where DIARRHOEA is reported as a complication: 0.7758%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DIARRHOEA:

ASPIRIN (8825 patients)
FOSAMAX (6626 patients)
HUMIRA (5790 patients)
SANDOSTATIN LAR (5337 patients)
NEXAVAR (4595 patients)
NEXIUM (4468 patients)
PREDNISONE (4401 patients)
LASIX (4335 patients)
LISINOPRIL (4076 patients)
LIPITOR (4061 patients)
HEPARIN SODIUM INJECTION (3985 patients)
OMEPRAZOLE (3884 patients)
SYNTHROID (3699 patients)
VIOXX (3665 patients)
METFORMIN HCL (3603 patients)
BYETTA (3578 patients)
EXJADE (3553 patients)
XELODA (3384 patients)
FLUOROURACIL (3286 patients)
METHOTREXATE (3275 patients)
ZOMETA (3124 patients)
REMICADE (3063 patients)
FOLIC ACID (3058 patients)
ATENOLOL (3014 patients)
FUROSEMIDE (2965 patients)
SIMVASTATIN (2942 patients)
DEXAMETHASONE (2806 patients)
COUMADIN (2790 patients)
ENBREL (2737 patients)
ACETAMINOPHEN (2691 patients)
REVLIMID (2646 patients)
PRILOSEC (2644 patients)
HYDROCHLOROTHIAZIDE (2606 patients)
CAPECITABINE (2587 patients)
XANAX (2520 patients)
FORTEO (2455 patients)
ZOLOFT (2430 patients)
PLAVIX (2382 patients)
LEVOTHYROXINE SODIUM (2367 patients)
NORVASC (2357 patients)
TYKERB (2339 patients)
PROTONIX (2338 patients)
ALLOPURINOL (2334 patients)
OXALIPLATIN (2295 patients)
NEURONTIN (2294 patients)
PREDNISOLONE (2287 patients)
DIGOXIN (2284 patients)
VITAMIN D (2277 patients)
LYRICA (2239 patients)
POTASSIUM CHLORIDE (2229 patients)
TOPROL-XL (2214 patients)
AMBIEN (2189 patients)
SEROQUEL (2155 patients)
OXYCONTIN (2143 patients)
CISPLATIN (2080 patients)
CYMBALTA (2067 patients)
ZOFRAN (2060 patients)
LORAZEPAM (2056 patients)
PREVACID (1990 patients)
PAXIL (1988 patients)
ZOCOR (1982 patients)
CELEBREX (1967 patients)
ATIVAN (1937 patients)
LEXAPRO (1911 patients)
ALBUTEROL (1828 patients)
CRESTOR (1818 patients)
IBUPROFEN (1796 patients)
CHANTIX (1795 patients)
PREDNISONE TAB (1769 patients)
VELCADE (1758 patients)
DECADRON (1745 patients)
DIOVAN (1722 patients)
LANTUS (1712 patients)
CYCLOPHOSPHAMIDE (1702 patients)
CALCIUM (1700 patients)
GABAPENTIN (1693 patients)
CARBOPLATIN (1685 patients)
AREDIA (1673 patients)
GLUCOPHAGE (1645 patients)
VICODIN (1641 patients)
METOPROLOL TARTRATE (1627 patients)
GLEEVEC (1619 patients)
LEVAQUIN (1554 patients)
TYSABRI (1552 patients)
AVONEX (1538 patients)
AMLODIPINE (1538 patients)
WARFARIN SODIUM (1536 patients)
PERCOCET (1524 patients)
RIBAVIRIN (1522 patients)
YAZ (1518 patients)
AVASTIN (1485 patients)
OXYCODONE HCL (1458 patients)
IMODIUM (1449 patients)
NIASPAN (1431 patients)
MULTI-VITAMINS (1425 patients)
SUTENT (1416 patients)
YASMIN (1407 patients)
MULTI-VITAMIN (1394 patients)
CLONAZEPAM (1366 patients)
ZANTAC (1335 patients)
LANSOPRAZOLE (1331 patients)
INSULIN (1330 patients)
DOCETAXEL (1325 patients)
PREMARIN (1309 patients)
MORPHINE (1291 patients)
PEGASYS (1282 patients)
EFFEXOR (1270 patients)
LEUCOVORIN CALCIUM (1257 patients)
ALLI (1255 patients)
MYCOPHENOLATE MOFETIL (1252 patients)
ADVAIR DISKUS 100/50 (1236 patients)
TYLENOL (CAPLET) (1232 patients)
PROZAC (1230 patients)
TRAMADOL HCL (1223 patients)
BONIVA (1211 patients)
ALPRAZOLAM (1209 patients)
AMOXICILLIN (1202 patients)
CYCLOSPORINE (1199 patients)
ACTOS (1197 patients)
COREG (1193 patients)
METFORMIN (1191 patients)
IRINOTECAN HCL (1179 patients)
COMPAZINE (1170 patients)
BEVACIZUMAB (1166 patients)
TAXOTERE (1164 patients)
KLONOPIN (1159 patients)
VICTOZA (1151 patients)
RAMIPRIL (1145 patients)
TACROLIMUS (1116 patients)
FLUCONAZOLE (1115 patients)
ACYCLOVIR (1111 patients)
METOPROLOL (1104 patients)
DURAGESIC-100 (1103 patients)
SPIRONOLACTONE (1099 patients)
VITAMIN B-12 (1092 patients)
SINGULAIR (1087 patients)
CIPROFLOXACIN (1074 patients)
BACTRIM (1063 patients)
PROGRAF (1056 patients)
ACCUTANE (1053 patients)
GLIPIZIDE (1045 patients)
CALCIUM CARBONATE (1045 patients)
COZAAR (1042 patients)
ASCORBIC ACID (1038 patients)
PRADAXA (1028 patients)
AVELOX (1018 patients)
RANITIDINE (1010 patients)
WELLBUTRIN (1008 patients)
CELEXA (1001 patients)
PACLITAXEL (1001 patients)
SPIRIVA (991 patients)
DIAZEPAM (987 patients)
ENALAPRIL MALEATE (986 patients)
FISH OIL (985 patients)
LAPATINIB (982 patients)
BENADRYL (972 patients)
ACTONEL (972 patients)
LOMOTIL (971 patients)
TRAZODONE HCL (963 patients)
ZYRTEC (960 patients)
LORTAB (950 patients)
NITROGLYCERIN (950 patients)
KALETRA (942 patients)
VANCOMYCIN (931 patients)
PANTOPRAZOLE (926 patients)
METOCLOPRAMIDE (926 patients)
TYLENOL (920 patients)
ONDANSETRON (912 patients)
VALIUM (910 patients)
FENTANYL (909 patients)
CIMZIA (908 patients)
GLYBURIDE (906 patients)
IRESSA (902 patients)
FLAGYL (899 patients)
AVANDIA (890 patients)
ARANESP (888 patients)
AMARYL (885 patients)
ALLEGRA (884 patients)
ALDACTONE (884 patients)
AUGMENTIN '125' (883 patients)
TARCEVA (880 patients)
FERROUS SULFATE TAB (871 patients)
NEUPOGEN (870 patients)
LOVENOX (869 patients)
HERCEPTIN (859 patients)
ZITHROMAX (859 patients)
ZELNORM (857 patients)
LOPRESSOR (840 patients)
TAXOL (839 patients)
FAMOTIDINE (839 patients)
MORPHINE SULFATE (832 patients)
VITAMIN E (828 patients)
REGLAN (827 patients)
ALTACE (814 patients)
ZETIA (814 patients)
PEPCID (806 patients)
DIFLUCAN (806 patients)
CITALOPRAM HYDROBROMIDE (801 patients)
CETUXIMAB (801 patients)
DOXORUBICIN HCL (796 patients)
NEORAL (795 patients)
ALENDRONATE SODIUM (790 patients)
SOLIRIS (789 patients)
DILAUDID (786 patients)
ERLOTINIB HYDROCHLORIDE (778 patients)
PANTOPRAZOLE SODIUM (772 patients)
AMITRIPTYLINE HCL (770 patients)
IRON (768 patients)
NAPROXEN (767 patients)
FLEXERIL (766 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DIARRHOEA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.